IQVIA Holdings Inc. (0JDM.L)
USD 147.96
(3.19%)
USD 147.96
(3.19%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 14.98 Billion USD | 4.13% |
| 2022 | 14.41 Billion USD | 3.86% |
| 2021 | 13.87 Billion USD | 22.14% |
| 2020 | 11.35 Billion USD | 2.44% |
| 2019 | 11.08 Billion USD | 6.49% |
| 2018 | 10.41 Billion USD | 6.91% |
| 2017 | 9.73 Billion USD | 41.6% |
| 2016 | 6.87 Billion USD | 19.88% |
| 2015 | 5.73 Billion USD | 5.08% |
| 2014 | 5.45 Billion USD | 7.07% |
| 2013 | 5.09 Billion USD | 4.81% |
| 2012 | 4.86 Billion USD | 12.43% |
| 2011 | 4.32 Billion USD | 10.29% |
| 2010 | 3.92 Billion USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 3.89 Billion USD | 2.15% |
| 2024 Q1 | 3.74 Billion USD | -4.32% |
| 2024 Q2 | 3.81 Billion USD | 1.98% |
| 2023 Q4 | 3.9 Billion USD | 4.63% |
| 2023 Q3 | 3.73 Billion USD | 0.21% |
| 2023 Q1 | 3.65 Billion USD | -2.33% |
| 2023 Q2 | 3.72 Billion USD | 2.08% |
| 2023 FY | 15 Billion USD | 4.13% |
| 2022 Q3 | 3.56 Billion USD | 0.59% |
| 2022 Q1 | 3.56 Billion USD | -1.87% |
| 2022 Q4 | 3.73 Billion USD | 4.97% |
| 2022 Q2 | 3.54 Billion USD | -0.76% |
| 2022 FY | 14.41 Billion USD | 3.86% |
| 2021 Q1 | 3.4 Billion USD | 3.37% |
| 2021 Q2 | 3.43 Billion USD | 0.85% |
| 2021 Q3 | 3.39 Billion USD | -1.37% |
| 2021 FY | 13.87 Billion USD | 22.14% |
| 2021 Q4 | 3.63 Billion USD | 7.23% |
| 2020 Q1 | 2.75 Billion USD | -4.87% |
| 2020 Q4 | 3.29 Billion USD | 18.38% |
| 2020 Q2 | 2.52 Billion USD | -8.46% |
| 2020 Q3 | 2.78 Billion USD | 10.51% |
| 2020 FY | 11.35 Billion USD | 2.44% |
| 2019 Q1 | 2.68 Billion USD | -0.15% |
| 2019 FY | 11.08 Billion USD | 6.49% |
| 2019 Q2 | 2.74 Billion USD | 2.09% |
| 2019 Q3 | 2.76 Billion USD | 1.06% |
| 2019 Q4 | 2.89 Billion USD | 4.55% |
| 2018 Q1 | 2.56 Billion USD | -0.54% |
| 2018 FY | 10.41 Billion USD | 6.91% |
| 2018 Q4 | 2.68 Billion USD | 3.62% |
| 2018 Q3 | 2.59 Billion USD | 1.05% |
| 2018 Q2 | 2.56 Billion USD | 0.16% |
| 2017 Q2 | 2.37 Billion USD | 2.28% |
| 2017 Q1 | 2.32 Billion USD | -0.68% |
| 2017 Q4 | 2.57 Billion USD | 4.54% |
| 2017 Q3 | 2.46 Billion USD | 3.79% |
| 2017 FY | 9.73 Billion USD | 41.6% |
| 2016 Q1 | 1.49 Billion USD | -2.08% |
| 2016 Q3 | 1.49 Billion USD | -3.57% |
| 2016 Q2 | 1.55 Billion USD | 4.2% |
| 2016 FY | 6.87 Billion USD | 19.88% |
| 2016 Q4 | 2.33 Billion USD | 56.16% |
| 2015 FY | 5.73 Billion USD | 5.08% |
| 2015 Q4 | 1.52 Billion USD | 6.81% |
| 2015 Q3 | 1.42 Billion USD | -1.3% |
| 2015 Q2 | 1.44 Billion USD | 7.12% |
| 2015 Q1 | 1.34 Billion USD | -4.5% |
| 2014 Q4 | 1.41 Billion USD | 0.79% |
| 2014 Q3 | 1.4 Billion USD | 4.4% |
| 2014 Q1 | 1.3 Billion USD | -5.17% |
| 2014 FY | 5.45 Billion USD | 7.07% |
| 2014 Q2 | 1.34 Billion USD | 2.54% |
| 2013 Q3 | 1.19 Billion USD | -7.71% |
| 2013 Q4 | 1.37 Billion USD | 15.33% |
| 2013 FY | 5.09 Billion USD | 4.81% |
| 2013 Q1 | 1.22 Billion USD | -3.89% |
| 2013 Q2 | 1.29 Billion USD | 5.44% |
| 2012 Q1 | 1.15 Billion USD | 0.0% |
| 2012 Q3 | 1.19 Billion USD | -2.53% |
| 2012 Q4 | 1.27 Billion USD | 6.59% |
| 2012 FY | 4.86 Billion USD | 12.43% |
| 2012 Q2 | 1.23 Billion USD | 6.41% |
| 2011 FY | 4.32 Billion USD | 10.29% |
| 2010 FY | 3.92 Billion USD | 0.0% |
| 2001 Q3 | 3.56 Billion USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 65.037% |
| Dynavax Technologies Corporation | 232.28 Million USD | -6350.724% |
| Illumina, Inc. | 4.5 Billion USD | -232.682% |
| Biogen Inc. | 9.83 Billion USD | -52.345% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -1260118.671% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | -295.533% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -1105.145% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -2366.417% |
| Waters Corporation | 2.95 Billion USD | -406.83% |
| Perrigo Company plc | 4.65 Billion USD | -221.849% |
| uniQure N.V. | 15.84 Million USD | -94478.047% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -55762.506% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -3652.041% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -174681.29% |
| bluebird bio, Inc. | 29.49 Million USD | -50698.386% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -71361.274% |
| Imunon, Inc. | - USD | -Infinity% |
| Myriad Genetics, Inc. | 678.4 Million USD | -2108.726% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -694.023% |
| Nektar Therapeutics | 90.12 Million USD | -16526.351% |
| Editas Medicine, Inc. | 78.12 Million USD | -19080.011% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 89.852% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -11694.339% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -519.372% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -8402.429% |
| Evolus, Inc. | 202.08 Million USD | -7314.702% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -47850.334% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | -14.232% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -12780.155% |
| FibroGen, Inc. | 147.75 Million USD | -10041.318% |
| Agilent Technologies, Inc. | 6.83 Billion USD | -119.289% |
| OPKO Health, Inc. | 863.49 Million USD | -1635.274% |
| Homology Medicines, Inc. | -6.65 Million USD | 225389.43% |
| Geron Corporation | 237 Thousand USD | -6322262.869% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -719.563% |
| Exelixis, Inc. | 1.83 Billion USD | -718.705% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -41206.685% |
| Zoetis Inc. | 8.54 Billion USD | -75.375% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -5437.324% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -428014.286% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | -51.826% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -1802.375% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -3006.297% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -1706.927% |
| Blueprint Medicines Corporation | 249.38 Million USD | -5908.501% |
| Insmed Incorporated | 305.2 Million USD | -4809.439% |
| TG Therapeutics, Inc. | 233.66 Million USD | -6312.682% |
| Incyte Corporation | 3.69 Billion USD | -305.45% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -1328.0% |